AI Article Synopsis
- Maintenance pemetrexed shows a survival advantage with manageable side effects for patients with advanced non-squamous non-small cell lung cancer (NSCLC).
- Three patients with oligoprogressive NSCLC received stereotactic ablative radiotherapy (SABR) while continuing maintenance pemetrexed.
- This combination treatment resulted in effective local control of the disease and prolonged progression-free survival, indicating it may be a beneficial strategy to maximize the effects of pemetrexed.
Article Abstract
Maintenance pemetrexed offers survival benefit with well-tolerated toxicities for advanced non-squamous non-small cell lung cancer (NSCLC). We present 3 consecutively enrolled patients with advanced non-squamous NSCLC, receiving stereotactic ablative radiotherapy (SABR) for oligoprogressive disease during maintenance pemetrexed. All of them had sustained local control of thoracic oligoprogression after the SABR, while maintenance pemetrexed were kept for additionally long progression-free interval. SABR targeting oligoprogression with continued pemetrexed is an effective and safe approach to extend exposure of maintenance pemetrexed, thus maximizing the benefit from it.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5043363 | PMC |
| http://dx.doi.org/10.1159/000448804 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!